Ann: Prospectus, page-65

Its good discussion going on here, despite differeing opinions its good to see back and forth and debate grounded in knowledge. Its quite refreshing actually and I think speaks well of the holders and those watching this stock.


The EV valuation is puzzling now, wonder if its Hoppers involvement that causes EV to be not worth a thing? In seriousness its probably due to the knowledge that funding is going to be needed very soon even with the recent raising.

Last quarterly had $3.1 mill in bank, they just got another $5 mill @ 0.008 + 4.1 mill R&D grant (however need to take off 1.5 mill to repay Endpoints advance)

Which leaves cash balance at approx: $10.7 mill.

Given since inception which was Jan 21, they have lost 66 mill, it means there is average burn rate of approx $4.5 mill a quarter.

Current cash at bank then allows for about 6 months at the latest before another raise, that is unless of course they can get the options in the money, which would trigger another $5 mill injection, which really only gives them another 3 months. Expensive business.

I caught one of Rebecca’s interviews—sounds like the trials require a 28-day gap between patients, which makes having multiple trials running at once a blessing or more rightly put a necessity (dont want to be paying those millions out for staff to do nothing for 4 months a year).

Let’s be honest, if they have to raise again at these levels, it’s going to sting. Management really needs to nail the timing here, and after watching how they handled the last raise, let’s just say their financial finesse doesn’t inspire a ton of confidence.

Here’s the question that matters and im genuinely curious from holders who know the company: with 4-6 months max before another raise is likely, what’s the timeline for catalysts that could push this stock past 0.008? Any trial results or key updates expected soon that could re-rate the company? Holders, what are you banking on? Let’s hear the playbook.